These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39268974)

  • 41. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
    Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High Frequency of Copy-Neutral Loss of Heterozygosity in Patients with Myelofibrosis.
    Rego de Paula Junior M; Nonino A; Minuncio Nascimento J; Bonadio RS; Pic-Taylor A; de Oliveira SF; Wellerson Pereira R; do Couto Mascarenhas C; Forte Mazzeu J
    Cytogenet Genome Res; 2018; 154(2):62-70. PubMed ID: 29587261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
    Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
    Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in
    Wang Y; Ran F; Lin J; Zhang J; Ma D
    Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
    Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
    Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical application of gene mutation information in myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
    Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
    Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
    Basim Najm M; Jalal SD; Getta HA
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):202-209. PubMed ID: 36800830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
    Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
    Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutational profiling in myelofibrosis: implications for management.
    Bose P; Verstovsek S
    Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
    J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
    ElNahass YH; Mahmoud HK; Mattar MM; Fahmy OA; Samra MA; Abdelfattah RM; ElRefaey FA; Fahmy HM; Fathy GM; Abdulgawad A; AbdelKader M; Elleithy HN; Gamil M; Talaat M; Nader HA; ElMetnawy WH
    Leuk Lymphoma; 2018 Apr; 59(4):844-854. PubMed ID: 28828906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
    Cazzola M; Kralovics R
    Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
    Lang T; Nie Y; Wang Z; Huang Q; An L; Wang Y; Wufuer G; Maimaiti A; Fu L; Li Y; Zhang X; Aisimutula A; Wang X; Zhu L; Liu H; Mao M
    J Int Med Res; 2018 Nov; 46(11):4650-4659. PubMed ID: 30084272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.